University of Wollongong

Research Online
Illawarra Health and Medical Research Institute

Faculty of Science, Medicine and Health

2017

A multicentre, randomised controlled, noninferiority trial, comparing nasal high flow with
nasal continuous positive airway pressure as
primary support for newborn infants with early
respiratory distress born in Australian non-tertiary
special care nurseries (the HUNTER trial): study
protocol
Brett Manley
Royal Women's Hospital, University of Melbourne

Calum Roberts
Royal Women's Hospital, University of Melbourne

Gaston Arnolda
University of New South Wales

Ian M. R Wright
University of Wollongong, Wollongong Hospital, University of Newcastle, iwright@uow.edu.au

Publication Details
Manley, B. J., Roberts, C. T., Arnolda, G. R. B., Wright, I. M. R., Owen, L. S., Dalziel, K. M., Foster, J. P., Davis, P. G. & Buckmaster, A.
G. (2017). A multicentre, randomised controlled, non-inferiority trial, comparing nasal high flow with nasal continuous positive
airway pressure as primary support for newborn infants with early respiratory distress born in Australian non-tertiary special care
nurseries (the HUNTER trial): study protocol. BMJ Open, 7 (6), e016746-1-e016746-9.

Research Online is the open access institutional repository for the University of Wollongong. For further information contact the UOW Library:
research-pubs@uow.edu.au

Louise Owen
University of Melbourne, Murdoch Children's Research Institute, Royal Women's Hospital
See next page for additional authors

A multicentre, randomised controlled, non-inferiority trial, comparing
nasal high flow with nasal continuous positive airway pressure as primary
support for newborn infants with early respiratory distress born in
Australian non-tertiary special care nurseries (the HUNTER trial): study
protocol
Abstract

Introduction Nasal high-flow (nHF) therapy is a popular mode of respiratory support for newborn infants.
Evidence for nHF use is predominantly from neonatal intensive care units (NICUs). There are no randomised
trials of nHF use in non-tertiary special care nurseries (SCNs). We hypothesise that nHF is non-inferior to
nasal continuous positive airway pressure (CPAP) as primary support for newborn infants with respiratory
distress, in the population cared for in non-tertiary SCNs.
Methods and analysis The HUNTER trial is an unblinded Australian multicentre, randomised, noninferiority trial. Infants are eligible if born at a gestational age ¿31 weeks with birth weight ¿1200 g and
admitted to a participating non-tertiary SCN, are 1 hour. Infants are randomised to treatment with either nHF
or CPAP. The primary outcome is treatment failure within 72 hours of randomisation, as determined by
objective oxygenation, apnoea or blood gas criteria or by a clinical decision that urgent intubation and
mechanical ventilation, or transfer to a tertiary NICU, is required. Secondary outcomes include incidence of
pneumothorax requiring drainage, duration of respiratory support, supplemental oxygen and hospitalisation,
costs associated with hospital care, cost-effectiveness, parental stress and satisfaction and nursing workload.
Ethics and dissemination Multisite ethical approval for the study has been granted by The Royal Children's
Hospital, Melbourne, Australia (Trial Reference No. 34222), and by each participating site. The trial is
currently recruiting in eight centres in Victoria and New South Wales, Australia, with one previous site no
longer recruiting. The trial results will be published in a peer-reviewed journal and will be presented at
national and international conferences.
Trial registration number Australian and New Zealand Clinical Trials Registry (ANZCTR):
ACTRN12614001203640; pre-results.
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ABSTRACT
Introduction Nasal high-flow (nHF) therapy is a popular
mode of respiratory support for newborn infants. Evidence
for nHF use is predominantly from neonatal intensive care
units (NICUs). There are no randomised trials of nHF use in
non-tertiary special care nurseries (SCNs). We hypothesise
that nHF is non-inferior to nasal continuous positive airway
pressure (CPAP) as primary support for newborn infants
with respiratory distress, in the population cared for in
non-tertiary SCNs.
Methods and analysis The HUNTER trial is an unblinded
Australian multicentre, randomised, non-inferiority trial.
Infants are eligible if born at a gestational age ≥31 weeks
with birth weight ≥1200 g and admitted to a participating
non-tertiary SCN, are <24 hours old at randomisation and
require non-invasive respiratory support or supplemental
oxygen for >1 hour. Infants are randomised to treatment
with either nHF or CPAP. The primary outcome is treatment
failure within 72 hours of randomisation, as determined by
objective oxygenation, apnoea or blood gas criteria or by
a clinical decision that urgent intubation and mechanical
ventilation, or transfer to a tertiary NICU, is required.
Secondary outcomes include incidence of pneumothorax
requiring drainage, duration of respiratory support,
supplemental oxygen and hospitalisation, costs associated
with hospital care, cost-effectiveness, parental stress and
satisfaction and nursing workload.
Ethics and dissemination Multisite ethical approval
for the study has been granted by The Royal Children’s
Hospital, Melbourne, Australia (Trial Reference No. 34222),
and by each participating site. The trial is currently
recruiting in eight centres in Victoria and New South Wales,
Australia, with one previous site no longer recruiting. The
trial results will be published in a peer-reviewed journal and
will be presented at national and international conferences.

Strengths and limitations of this study
►► This is the first study to compare nasal high-flow

with nasal continuous positive airway pressure as
respiratory support for newborn infants in nontertiary settings.
►► The study is well-powered to detect non-inferiority
of nasal high-flow with a non-inferiority margin of
10%; the use of a non-inferiority study design is
appropriate given the advantages of nasal high-flow
over nasal continuous positive airway pressure.
►► The study includes assessment of parental stress,
nursing workload and financial costs.
►► Blinding of the allocated respiratory support modes
is not possible, so objective criteria were specified
for the primary outcome of treatment failure.
►► Some infants in the nasal high-flow group will have
received a brief period of nasal continuous positive
airway pressure prior to randomisation.
Trial registration number Australian and New Zealand
Clinical Trials Registry (ANZCTR): ACTRN12614001203640;
pre-results.

Introduction
Background
Preterm birth, at <37 weeks’ gestational
age (GA), affecting about 15 million infants
annually, is a major cause of morbidity and
mortality worldwide. About one million
infants die from complications of prematurity every year.1 In Australia, about 9% of all
births are preterm.2 A major contributor to
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mortality and morbidity in preterm infants is respiratory
distress syndrome (RDS) due to surfactant deficiency in
the lungs, which leads to many preterm infants requiring
respiratory support soon after birth; the proportion
of infants who develop RDS increases with lower GA.
However, about 80% of preterm infants are born
moderate to late preterm (32–36 weeks’ GA),2 where
RDS is less common. Respiratory symptoms in this more
mature preterm population, and in term infants, may be
due to conditions such as transient tachypnoea of the
newborn or infection.
It is estimated that 2.5%–5% of all newborn infants have
respiratory distress.3 In Australia, most of these infants are
born in a non-tertiary hospital and cared for in a special
care nursery (SCN), where (depending on the level of
neonatal care available) they may be treated with supplemental oxygen and/or ‘non-invasive’ respiratory support
from nasal continuous positive airway pressure (CPAP).
However, if these treatments are not available such as in
some smaller SCNs, or not successful, or if an infant is
born very preterm (<32 weeks’ gestation) or very small
(<1250 g), then the infant usually needs to be transferred
to a tertiary-level neonatal intensive care unit (NICU). In
Australia, neonatal intensive care is centralised in large
metropolitan centres, and maternal and infant transfers
from regional or rural centres involve large distances and
significant costs.
The standard non-invasive respiratory support: CPAP
CPAP uses large prongs in the nose, or a mask over the
nose, fitted firmly to the infant’s face. The prongs or mask
deliver heated and humidified air and oxygen under
pressure. CPAP can be used effectively as the primary
mode of respiratory support (the first mode of respiratory support applied after admission to the neonatal unit
soon after birth) in infants with respiratory distress, even
those born at 25–30 weeks’ gestation.4 5 When used in
Australian non-tertiary SCNs to treat late preterm and
term infants with respiratory distress, CPAP reduces the
need for transfer to a tertiary NICU, and it reduces costs
in comparison to the use of supplemental oxygen alone.6
However, CPAP has been associated with an increased risk
of pneumothorax compared with supplemental oxygen
alone.6 7
CPAP is a widely used method of respiratory support
in larger Australian SCNs,8 9 but it has some disadvantages. CPAP fixation devices are bulky and cover much
of the infant’s face, interfering with parental interaction and feeding; trauma to the nasal skin or septum is
a commonly reported complication.10 Nursing vigilance
is required to ensure that an adequate seal (and hence
pressure) is maintained without causing nasal injury. For
these reasons, and others including limits on staff and
equipment, CPAP is not currently a feasible therapy in
smaller Australian SCNs (with birth rates mostly <1500/
year) that infrequently care for infants who require respiratory support.
2

The new therapy: nasal high-flow
In recent years, nasal high-flow (nHF) therapy, a newer
form of non-invasive respiratory support, has become
popular as an alternative to CPAP around the world,
including in Australasian SCNs.9 11–15 nHF therapy delivers
heated, humidified, blended oxygen and air via small
binasal prongs, using gas flows of at least 1 L/min.16 While
nHF therapy has been adopted by many NICUs around
the world, there has until recently been relatively little
evidence to support this practice. The increasing popularity of nHF seems to be due to its reported advantages
over CPAP: it is easier to apply and maintain, more
comfortable for infants, associated with less nasal trauma
and preferred by parents and nursing staff.17–20 If nHF
was demonstrated to be an effective mode of respiratory
support in non-tertiary SCNs, these factors would make it
the preferred interface in this setting.
Clinical trials of nHF in newborn infants
Preventing extubation failure in NICUs
The majority of published randomised controlled trials
(RCTs) of nHF have evaluated its use as an alternative to CPAP, as postextubation respiratory support. An
updated Cochrane Review20 of these trials, published in
2016, found no difference in rates of treatment failure or
reintubation in infants treated with postextubation nHF,
compared with those treated with CPAP. The nHF infants
were noted to have lower rates of nasal trauma and a small
reduction in the risk of pneumothorax.
Primary respiratory support for newborn infants
Prior to the HUNTER trial commencing, there was little
evidence from RCTs to support the use of nHF as primary
support for newborn infants. Yoder et al21 conducted
an RCT in 432 infants, of whom about one-third were
included in an ‘early support’ arm. There was no difference between the nHF and CPAP groups in need for
intubation or in other neonatal morbidities. Studies by
Iranpour et al22 and Kugelman et al,23 each including
approximately 70 infants, compared nHF with CPAP and
nasal intermittent positive airway pressure, respectively, as
early respiratory support for preterm infants; they found
no difference between groups in rates of treatment failure
or other important outcomes.
Within the past year, two larger RCTs evaluating nHF
as primary respiratory support in NICUs have been
published. The HIPSTER trial24 included 564 preterm
infants of mean 32 weeks’ GA and 1.7 kg in birth weight,
not previously treated with surfactant, in nine NICUs in
Australia and Norway; nHF use resulted in a higher rate
of treatment failure (based on objective clinical criteria)
than CPAP (25.5% vs 13.3%, p<0.01), but no greater
risk of intubation, likely due to the use of ‘rescue’ CPAP
in infants with nHF failure. Lavizzari et al25 studied 316
infants of mean 33 weeks’ GA and 1.9 kg in birth weight
in an Italian NICU. They found no difference in rates of
treatment failure (mechanical ventilation within 72 hours)
between infants treated with nHF and those treated with
Manley BJ, et al. BMJ Open 2017;7:e016746. doi:10.1136/bmjopen-2017-016746
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CPAP and/or biphasic positive airway pressure (10.8% vs
9.5%, p=0.71). However, it is notable that infants in this
study could be intubated, treated with surfactant and
extubated (‘INSURE’ treatment), without being classed
as having treatment failure. Surfactant use was common,
occurring in >40% of infants in both treatment groups.
While providing important guidance on the use of
primary nHF in NICUs, it is important to recognise that
the results of these studies cannot be directly applied
to use in non-tertiary SCNs, where there is currently no
high-quality evidence to guide practice. Staffing in SCNs
is different to that in tertiary NICUs, and infants in SCNs
have different antenatal exposures, GAs and pathologies.
Summary and rationale
The reported advantages of nHF—easier nursing care,
improved feeding and parental interaction, reduced nasal
trauma and greater infant comfort—have led to widespread adoption of this new therapy. While there are now
a number of studies assessing nHF use in the NICU, there
are no published trials that study the efficacy and safety
of nHF compared with CPAP as early respiratory support
for newborn infants in SCNs. The reference treatment
against which non-inferiority is being assessed, CPAP,
has been shown to be effective in SCNs in a study with
similar inclusion criteria and CPAP treatment protocols.6
If proven to be effective and safe, the ease of use of nHF
would mean that it could be widely applied to infants with
respiratory distress in non-tertiary SCNs, both in Australia
and around the world, potentially reducing the need for
transfer to a tertiary NICU—reducing costs and keeping
mothers and their babies together. Conversely, if nHF
is shown to be unsafe or significantly less effective than
CPAP, this will guide clinicians to avoid nHF treatment
of newborn infants outside NICUs. The above considerations led to the adoption of a non-inferiority trial design.
Methods and analysis
Study design
HUNTER is a multicentre, randomised, non-inferiority
trial, including newborn infants cared for in Australian
non-tertiary SCNs, who require early non-invasive respiratory support in the first 24 hours of life. A schedule of
enrolment, interventions and assessments is shown in the
figure.
Aim
The aim of the HUNTER trial is to determine whether
nHF is non-inferior to CPAP in avoiding treatment failure
when used as early non-invasive respiratory support for
newborn infants cared for in Australian non-tertiary
SCNs.
Blinding
Blinding of the allocated treatment is not feasible, as the
mode of respiratory support is clearly apparent to medical
and nursing staff and parents/guardians. We have therefore defined objective criteria for the primary outcome
Manley BJ, et al. BMJ Open 2017;7:e016746. doi:10.1136/bmjopen-2017-016746

Figure 1 Schedule of enrolment, interventions and
assessments: the HUNTER trial. HF, high flow; CPAP,
continuous positive airway pressure.

to minimise potential bias, and have provided guidance
to clinicians considering the need to escalate respiratory
support and/or arrange transfer to a tertiary NICU.
Outcomes
The primary outcome will be assessed on a hypothesis
of non-inferiority. Outcomes, eligibility criteria and the
CPAP treatment protocol are similar to those of a study in
Australian SCNs that demonstrated the efficacy of CPAP
in comparison to passive oxygen for preventing treatment
failure.6 The major change from that study is a reduction
in the fraction of inspired oxygen (FiO2) threshold for
treatment failure from 0.50 to 0.40, in line with current
international practice to reduce neonatal oxygen exposure.
Primary outcome
The primary outcome is treatment failure within 72 hours
of randomisation. Treatment failure occurs when an
infant has reached maximal therapy for their allocated
treatment (nHF 8 L/min or CPAP 8 cm H2O) and one or
more of the following criteria are satisfied:
1. Sustained increase in oxygen requirement: fraction of
inspired oxygen (FiO2) ≥0.40 for more than 1 hour to
maintain peripheral oxygen saturation (SpO2) 91%–
95%.
2. Respiratory acidosis: both pH <7.20 and pCO2 >60
millimetres of mercury (mm Hg) on two blood gas
samples (which can be capillary, venous or arterial),
with the first sample collected at least 1 hour after
initiation of the assigned treatment and the second
sample taken at least 1 hour after the first.
3. Frequent or severe apnoea: more than one apnoea
receiving positive pressure ventilation within any
24 hours period, or six or more apnoeas in any
6-hour period receiving intervention (stimulation or
increased oxygen).
3
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4. The treating paediatrician determines that urgent
intubation and mechanical ventilation is required.
5. The treating paediatrician determines that the
infant requires transfer to a tertiary NICU, through
consultation with the local neonatal transport service.
Secondary outcomes
The secondary outcomes are as follows:
1. Cost: estimated differences between the interventions
based on the costs of equipment, care in SCNs and
NICUs, costs associated with hospital stay, costs to
the family and the costs of transfer (both infant and
maternal).
2. Mortality (specified as a significant adverse event).
3. Pneumothorax requiring drainage via needle
thoracocentesis or intercostal catheter insertion
(specified as a significant adverse event).
4. Duration of supplemental oxygen (hours).
5. Oxygen supplementation at 28 days of age, or at
36 weeks’ corrected GA for infants born <32 weeks’
gestation.
6. Mechanical ventilation via an endotracheal tube in
the first 72 hours after randomisation and at any time
prior to discharge home.
7. Duration of respiratory support (hours): including
hours of nHF, CPAP and mechanical ventilation.
8. Duration of hospital admission and duration of
admission to a tertiary NICU (days).
9. Incidence of nasal trauma.
10. Weight gain and feeding performance, including
weight gain from birth to hospital discharge,
proportion of infants fully breastfed at discharge,
number of days receiving any intravenous fluids and
number of days to reach full suck feeds (defined as
tolerating suck feeds without any requirement for
intravenous fluids or nasogastric/orogastric feeds
for >24 hours).
11. Parental stress and satisfaction, measured using a
modified version of the validated Parental Stressor
Scale: NICU,26 assessed as soon as possible after
treatment has ceased, or prior to transfer to a NICU.
12. Nursing workload and treatment preference,
measured using the Professional Assessment of
Optimal Nursing Care Intensity Scale tool,27 and by
questionnaire.
Setting
The trial has been enrolling infants in nine non-tertiary
SCNs in Victoria and New South Wales, Australia. All
participating SCNs routinely care for newborn infants
with respiratory distress, using CPAP as the standard
non-invasive support mode; participating centres did not
previously use nHF to treat newborn infants. No Australian SCNs provide ongoing mechanical ventilation; this
is only provided while awaiting transfer of the infant
to a tertiary NICU. All participating centres administer
exogenous surfactant if the infant requires intubation for
RDS prior to retrieval by the neonatal transport team; the
4

standard of care is that all these infants are transferred
to a tertiary NICU. Two participating centres have some
experience using the ‘INSURE’ (Intubate, Surfactant,
Extubate) procedure28 in select infants with the support
of the neonatal transport service (after which NICU
transfer could potentially be avoided), but this is an infrequent practice that is staff dependent. The participating
SCNs have 24 hour on-site junior paediatric staff and a
designated on-call consultant paediatrician available to
advise management and/or attend as required. Some
participating centres have one or two consultant staff with
specialist neonatal training, but most Australian SCNs do
not.
Eligibility criteria
Infants are eligible for inclusion in the trial if:
1. They are born at ≥31 weeks’ GA by best obstetric
estimate and have birth weight ≥1200 g; and
2. They are admitted to the SCN of a participating centre
and are <24 hours old at the time of randomisation;
and
3. They require non-invasive respiratory support
after admission to the SCN (at clinician discretion)
or require any supplemental oxygen to maintain
SpO2 91%–95% for more than 1 hour.
Infants are excluded from the trial if:
1. They have received more than 2 hours of CPAP prior to
randomisation; or
2. They have previously been intubated (including
intubation for suctioning below the cords in the
delivery room), or immediately need intubation, as
determined by the attending paediatrician; or
3. They have a known major congenital abnormality
that may impact on the infant’s condition after birth
(eg, complex congenital cardiac disease, upper
airway obstruction, gastrointestinal malformation);
or
4. They are judged by their paediatrician to require
transfer to another hospital for ongoing care (the
reason for this decision will be clearly documented).
Randomisation
Randomisation will be prestratified by centre and
according to GA at birth: <34 weeks’ GA and ≥34 weeks’
GA. Within each stratum, a 1:1 allocation ratio and block
randomisation with variable block sizes (4, 6 or 8) will be
used. Multiple births with more than one eligible infant
will be randomised individually. Each participating centre
will be provided with consecutively numbered, sealed
opaque randomisation envelopes containing the assigned
treatment allocation. The appropriate envelope will be
opened after written consent has been obtained and
the infant has become eligible for the trial; the assigned
treatment will then immediately be applied to the infant.
Random sequences were generated in SAS v9.4 by author
Arnolda.
Manley BJ, et al. BMJ Open 2017;7:e016746. doi:10.1136/bmjopen-2017-016746
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Clinical management
Eligible and consented infants will be randomised to
treatment with either nHF or CPAP; allocated treatment
will be applied immediately after randomisation. Infants
in both groups will receive standard supportive care as
per local policies, for example, blood tests, antibiotics,
intravenous fluids/nutrition and enteral feeds. In both
groups, supplemental oxygen will be adjusted to maintain SpO2 91%–95%. Chest X-rays and blood gas analyses
are not mandated prior to randomisation, and the timing
of these investigations will be a physician discretion in
keeping with the pragmatic trial design; however, it is
expected that most enrolled infants will have these investigations performed as per local guidelines.
Interventions
nHF therapy is defined as heated, humidified gas
(blended air/oxygen) delivered at gas flows of 5–8 L/
min via the Fisher & Paykel ‘Optiflow Junior’ circuit and
prongs (Fisher & Paykel Healthcare, Auckland, New
Zealand).
CPAP is defined as the use of short binasal prongs or
nasal mask to deliver heated, humidified gas (blended
air/oxygen) using a ‘bubble’ CPAP device (any brand
may be used) with set pressures of 5–8 cm H2O.
Intervention group: nHF
1. A nasal cannula size should be selected that maintains
a leak at the nares.
2. The starting flow will be 6 L/min for all infants.
3. Increasing nHF support: Gas flow may be increased to
a maximum of 8 L/min.
4. If treatment failure criteria are satisfied, infants
should receive CPAP 8 cm H2O and then be managed
as per the CPAP group protocol:
a. If treatment failure criteria are again satisfied
when the infant is receiving CPAP 8 cm H2O, it
is recommended that the treating paediatrician
consider referral to the local neonatal transport
service for advice and/or transfer of the infant to a
tertiary NICU, and surfactant may be administered
at the paediatrician’s discretion according to the
unit’s individual policy.
b. If the infant’s condition is improving, the CPAP
pressure should be weaned, and nHF may be
reinstituted at the paediatrician’s discretion.
5. Decreasing and ceasing nHF support.
a. Gas flow may be decreased (in decrements of 1 L/
min) or ceased if there is no supplemental oxygen
requirement (infant is receiving air), or if the
infant has required FiO2 <0.25 for >24 hours.
b. nHF should be ceased when the gas flow is 5 L/
min, and there is no supplemental oxygen
requirement, or the infant has required FiO2 <0.25
for >24 hours:
c. If nHF is ceased, infants may receive ongoing
oxygen supplementation via ‘low-flow’ nasal
cannulae, cot oxygen or head-box oxygen.
Manley BJ, et al. BMJ Open 2017;7:e016746. doi:10.1136/bmjopen-2017-016746

d. After ceasing nHF, if non-invasive breathing
support is again required, nHF should be
recommenced at ≥5 L/min and managed as above.
6. Infants randomised to nHF will not receive CPAP after
randomisation, unless treatment failure criteria are
met.
Standard care group: CPAP
1. The starting set pressure will be 6 cm H2O for all
infants.
2. Increasing CPAP support: the set CPAP pressure may
be increased to a maximum of 8 cm H2O.
3. If treatment failure criteria are satisfied, it is
recommended that the treating paediatrician
consider referral to the local neonatal transport
service for advice and/or transfer of the infant to a
tertiary NICU, and surfactant may be administered at
the paediatrician’s discretion according to the unit’s
individual policy.
4. Decreasing and ceasing CPAP support:
a. The set pressure may be decreased (in decrements
of 1 cm H2O) or ceased if there is no supplemental
oxygen requirement (infant is receiving air), or if
the infant has required FiO2 <0.25 for >24 hours.
b. CPAP should be ceased when the set pressure is
5 cm H2O, and there is no supplemental oxygen
requirement, or the infant has required FiO2 <0.25
for >24 hours.
c. If CPAP is ceased, infants may receive ongoing
oxygen supplementation via ‘low-flow’ nasal
cannulae, cot oxygen or head-box oxygen.
d. After ceasing CPAP, if non-invasive breathing
support is again required, CPAP should be
recommenced at ≥5 cm H2O and managed as
above.
5. Infants randomised to CPAP will not receive nHF at
any stage of their admission.
Sample size calculation
Non-inferiority of nHF will be determined using the absolute risk difference (RD) and 95% CI for the primary
outcome of treatment failure within 72 hours of randomisation. We have set the margin of non-inferiority at 10%.
Thus, for nHF to be non-inferior to CPAP, the upper
limit of the two-sided 95% CI of the RD must be <10%.
This margin was adopted after agreement between the
site investigators and our parent representative; it is
equivalent to the smallest margin chosen in previously
published non-inferiority trials of neonatal respiratory
support,25 29 and it is narrower than in most non-inferiority trials published in the adult medical literature.
Based on pretrial data from six non-tertiary SCNs, we
estimate the rate of the primary outcome in the CPAP
group will be 17%. A sample size of 750 infants (375
infants in each group) is required to demonstrate non-inferiority of nHF with 90% power: that is, to be 90% sure
that the upper limit of a two-sided 95% CI will exclude a
5
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difference in favour of CPAP of more than 10% (www.
sealedenvelope.com/power/binary-noninferior).
Statistical analysis and economic evaluation plan
Statistical analysis will be performed by authors Manley
and Arnolda with assistance from the Trial Steering
Committee. Data will be exported from an electronic database to an electronic statistical package for analysis. The
primary analysis will be by intention to treat. A secondary
per protocol analysis will also be performed for the primary
outcome and any important differences reported, as is
recommended for non-inferiority trials.30
The difference between the groups in the incidence of the
primary outcome will be reported using RD with two-sided
95% CI. Subgroup analysis by GA at birth will be performed
for the primary outcome and selected secondary outcomes.
Dichotomous secondary outcomes will be compared
with an RD (two-sided 95% CI) and a Χ2 test. Continuous
secondary outcomes will be compared by the appropriate
parametric (t-test) or non-parametric (Mann-Whitney U)
test. The primary outcome will be assessed on a hypothesis
of non-inferiority; all secondary outcomes will be assessed
against a hypothesis of superiority.
Cost-effectiveness analysis will be conducted from the
healthcare system perspective, incorporating the costs of
inpatient stay including the associated device and patient
transfer costs. Routinely available costs of inpatient stay
will be sourced from the hospital costing units. To inform
whether it is cost-effective to incorporate nHF or CPAP
into the existing health system, decision analysis will be
constructed based on the primary outcome and associated hospital costs. Univariate and probabilistic sensitivity
analyses will be conducted to test the impact of uncertainty in data.
Nursing workload measures will be analysed using
longitudinal methods, as these are provided by the
nurse primarily responsible for the infant at the hospital
of birth, for each shift in the first 72 hours of care after
randomisation.
Ethics and dissemination
Research ethics approval
Multisite ethical approval for the study has been granted by
The Royal Children’s Hospital, Melbourne, Australia (No.
34222, current approved protocol version 6, 15 May 2017).
Site-specific governance approval has been granted by
the following human research ethics committees: Victoria,
Australia: Western Health, Northern Health, Eastern
Health, Barwon Health and Monash Health; New South
Wales, Australia: Central Coast Local Health District and
Illawarra Shoalhaven Local Health District.
Recruitment and consent
In all cases, prospective, written consent will be obtained
from a parent or guardian. Consent may be either antenatal or postnatal.
For postnatal consent, eligible infants will be identified
after birth and their parents or guardians approached
6

as soon as possible for prospective consent. Parents or
guardians of infants who are not yet eligible but are likely
to become eligible (eg, infants requiring supplemental
oxygen who are likely to continue on this treatment) may
also be approached. In some cases, antenatal consent
may be obtained (eg, when a preterm birth is planned).
Written consent will be recorded on the trial patient
information and consent form.
Consent will be obtained by a doctor or nurse who has
been trained in obtaining consent for the trial and who has
received education regarding the trial protocol. Wherever
possible, consent will be obtained by someone not directly
involved in the clinical care of the infant at the time.
Data collection, storage and access
Data will be sourced from the infant’s bedside observation chart, medical and nursing notes, pathology results,
electronic monitors, the mother’s medical chart and
verbally and by questionnaire from parents/guardians
and nursing staff. Data will be de-identified and entered
onto a paper case record form and subsequently will be
entered into a secure, web-based electronic database.
Only the members of the Trial Steering Committee will
have access to the final dataset.
Monitoring and safety
An independent data safety and monitoring committee
(DSMC) has been convened, consisting of two neonatologists, a paediatric emergency specialist and a
statistician. An early safety review was undertaken after
150 infants were recruited to the trial, and further safety
reviews are planned approximately 6 monthly. A single
review of the primary outcome and its components was
planned, after the primary outcome was known for 375
participants.
Defined serious adverse events (SAEs) for the study are:
►► Air leak from the lung (pneumothorax) requiring
drainage via needle thoracocentesis or intercostal
catheter insertion.
►► Death before discharge from hospital.
All incidences of these SAEs are reported to the lead
Human Research Ethics Committee and to committees
at the relevant site.
The DSMC may make a recommendation to the
Steering Committee to temporarily or permanently stop
the trial. Although no formal stopping rule will be used,
such a decision may be based on:
►► A difference in the primary outcome such that the
committee considers the trial should no longer
continue.
►► An increase in the rate of SAEs in the nHF group.
►► Equipment failure or unforeseen complications
pertaining to the equipment or its manufacture.
►► New information such as other trial results which
make it ethically impossible to continue the trial.
The primary outcome review was completed in December
2016, and on the basis of this, and on safety reviews
Manley BJ, et al. BMJ Open 2017;7:e016746. doi:10.1136/bmjopen-2017-016746
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conducted to date, the DSMC has recommended that the
trial continue without modification.
Dissemination of results
The results of the trial will be published in a peer-reviewed journal and will be presented at national and
international conferences.
Current status and study duration
The trial began recruiting in April 2015, with additional
sites joining subsequently. It is currently recruiting in eight
centres, with one previous site ceasing recruitment due to a
change in its level of care classification, meaning that it could
no longer care for infants requiring prolonged non-invasive
respiratory support. To the end of March 2017, over 500
infants have been enrolled in the trial. It is expected that
recruitment for the study will be completed in 2018.
Discussion
nHF therapy has been widely adopted in neonatal practice due to its desirable qualities such as ease of use,
reduced nasal trauma and parental and nursing preference.17–20 Recently, the HIPSTER trial demonstrated that
in NICUs, rates of treatment failure with nHF are higher
than with CPAP in preterm infants born ≥28 weeks’
GA, although with ‘rescue’ CPAP available there is no
difference in rates of intubation.24 The HIPSTER results
suggest that CPAP should be favoured over nHF if only
one treatment is available; however, these findings cannot
be directly applied to environments other than the NICU.
The other recently published trial of primary nHF was
also performed in a NICU and it included a high rate of
surfactant administration by the INSURE technique, an
intervention which is not currently practised routinely in
Australian SCNs, and that has not been well-studied in
the SCN setting or in the infant population relevant to
SCNs (infants ≥31 weeks’ GA).28
There has traditionally been a lack of clinical research
in newborn infants cared for in non-tertiary SCNs and
only one previous RCT of respiratory support in this
setting.6 Research in SCNs is important because care of
infants in these units incorporates a number of factors
distinct from tertiary NICUs. Non-tertiary SCNs do not
care for large numbers of very preterm or very low birth
weight infants and often need to treat term infants with
respiratory distress. The resources and staffing available
in non-tertiary SCNs are different from those in NICUs,
and while capable of intubation and mechanical ventilation as a stabilisation measure, SCNs are not equipped
to provide this level of treatment for longer periods. The
implications for failure of non-invasive support are therefore greater in SCNs: transfer of the infant to a NICU and
separation from his or her parents. Furthermore, there
are potentially important financial implications of treatment failure: retrieval by specialist neonatal transport
services, particularly when over long distances, as would
apply in many areas of Australia, bears a significant cost.
Manley BJ, et al. BMJ Open 2017;7:e016746. doi:10.1136/bmjopen-2017-016746

Transfers from SCNs also have an impact on staffing and
resource allocation in receiving tertiary NICUs.
There has never been a randomised trial of nHF in
non-tertiary SCNs; nHF may be an effective mode of
support in this setting and, due to its ease of use, would be
preferable to CPAP if shown to be non-inferior. However,
it is equally important to determine if nHF is unsafe or
significantly inferior to CPAP, so that clinicians may be
guided to avoid nHF use in non-tertiary SCNs. If nHF use
was associated with a reduction in nursing workload, it
may prove to be more cost-effective than CPAP or may
result in a greater capacity to manage infants requiring
non-invasive support in SCNs. CPAP is associated with
an increased risk of pneumothorax in comparison with
oxygen treatment.6 A Cochrane Review noted nHF
treatment to be associated with a small reduction in
pneumothorax rate compared with CPAP.20 If a lower
rate of this complication was seen in our trial with nHF,
in conjunction with non-inferiority in treatment efficacy,
nHF could be the preferred mode of treatment.
The HUNTER trial is a well-powered, carefully
designed randomised clinical trial, which will determine
whether nHF is an appropriate mode of early respiratory
support for newborn infants in the non-tertiary setting.
The non-inferiority design used in the HUNTER trial was
until recently quite rare but has been used recently in
similar trials by our group.24 31 The choice of non-inferiority margin of 10% was made in view of the fact that the
primary outcome was treatment failure and not a more
critical outcome, such as death, and that infants who have
treatment failure on nHF will be offered CPAP, which
may ‘rescue’ them from intubation and/or transfer to a
NICU, as seen in previous NICU trials of nHF.24 31 32
A potential limitation to this trial is that blinding of
treatment allocation is not possible. We have attempted to
minimise this by setting objective treatment failure criteria,
which were agreed on by all participating centres. Some
infants allocated to nHF will receive a brief period of CPAP
before randomisation, which conceivably could affect interpretation of the results. However, we have aimed to restrict
the impact of this by excluding infants who have received
two or more hours of CPAP from the trial, which we felt to
be the shortest window in which seeking parental consent
would be feasible. The HUNTER trial is a pragmatic trial,
designed to assess whether nHF is non-inferior to CPAP
in real-world practice. We have not mandated the need or
timing of investigations such as chest X-rays or blood gas
analysis nor have we protocolised the decision to treat
infants with non-invasive support, which remains at clinician
discretion. We acknowledge that some randomised infants
may have recovered from respiratory distress without the
use of non-invasive support or may have an unrecognised
pneumothorax if randomised prior to a chest X-ray being
performed.
The use of nHF in NICU practice is well-established
and supported by evidence from multiple RCTs. However,
nHF use is also being adopted in non-tertiary SCNs,9 13–15
a setting in which there is little evidence of its efficacy
7
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and safety. If this trial demonstrates that nHF is non-inferior to CPAP as primary support for newborn infants in
non-tertiary SCNs, then many units worldwide are likely
to incorporate nHF into their routine practice. However,
if nHF is inferior to CPAP, the results of this study will
ensure that this treatment is not applied inappropriately,
and infants in non-tertiary SCNs with respiratory distress
will continue to receive evidence-based care.
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